SUPPLEMENT

Supplementary Table 1. Quality Assessment of the 17 Included Studies

Study	NIH Quality Assessment Tool for Case Series Studies Criteria Met									Quality
	Q1	Q2	Q3	Q4	Q5	Q6	Q7	Q8	Q9	- Rating
Abenza-Abildúa et al. [1]	٧	V	V	NA	V	V	V	Х	V	Good
Agarwal et al. [2]	V	Χ	NR	NA	V	V	V	V	V	Fair
Chougar et al. [3]	V	V	V	NA	V	V	V	V	V	Good
Eliezer et al. [4]	V	V	NR	NA	V	V	V	V	V	Good
Freeman et al. [5]	V	V	V	NA	V	V	V	Χ	V	Good
Grewal et al. [6]	V	V	V	NA	V	V	٧	V	V	Good
Hernández-Fernández et al. [7]	V	V	V	NA	V	V	V	V	V	Good
Kandemirli et al. [8]	V	V	NR	NA	V	V	٧	V	V	Fair
Klironomos et al. [9]	V	V	V	NA	V	V	V	Χ	V	Good
Kremer et al. [10]	V	٧	NR	NA	V	٧	V	V	V	Good
Lin et al. [11]	V	V	V	NA	V	V	V	Χ	V	Good
Nawabi et al. [12]	V	V	V	NA	V	V	V	V	V	Good
Paterson et al. [13]	V	V	NR	NA	V	V	V	Χ	V	Fair
Radmanesh et al. [14]	V	V	NR	NA	V	٧	V	Χ	V	Fair
Radmanesh et al. [15]	V	V	V	NA	V	V	V	V	V	Good
Scullen et al. [16]	V	V	NR	NA	V	Χ	V	Χ	Χ	Fair
Yoon et al. [17]	V	V	NR	NA	V	V	V	V	V	Good

Fair = met 4–6 criteria, Good = met 7–9 criteria, NA = not applicable, NIH = National Institutes of Health, NR = not reported, Poor = met 0–3 criteria, Q1 = was the study question or objective clearly stated?, Q2 = was the study population clearly and fully described, including a case definition?, Q3 = were the cases consecutive?, Q4 = were the subjects comparable?, Q5 = was the intervention clearly described?, Q6 = were the outcome measures clearly defined, valid, reliable, and implemented consistently across all study participants?, Q7 = was the length of follow-up adequate?, Q8 = were the statistical methods well-described?, Q9 = were the results well-described?

REFERENCES

- 1. Abenza-Abildúa MJ, Ramírez-Prieto MT, Moreno-Zabaleta R, Arenas-Valls N, Salvador-Maya MA, Algarra-Lucas C, et al. Neurological complications in critical patients with COVID-19. *Neurologia* 2020;35:621-627
- 2. Agarwal S, Jain R, Dogra S, Krieger P, Lewis A, Nguyen V, et al. Cerebral microbleeds and leukoencephalopathy in critically ill patients with COVID-19. *Stroke* 2020;51:2649-2655
- 3. Chougar L, Shor N, Weiss N, Galanaud D, Leclercq D, Mathon B, et al. Retrospective observational study of brain MRI findings in patients with acute SARS-CoV-2 infection and neurologic manifestations. *Radiology* 2020;297:E313-E323
- 4. Eliezer M, Hamel AL, Houdart E, Herman P, Housset J, Jourdaine C, et al. Loss of smell in patients with COVID-19: MRI data reveal a transient edema of the olfactory clefts. *Neurology* 2020;95:e3145-e3152
- 5. Freeman CW, Masur J, Hassankhani A, Wolf RL, Levine JM, Mohan S. Coronavirus disease (COVID-19)-related disseminated leukoencephalopathy: a retrospective study of findings on brain MRI. *AJR Am J Roentgenol* 2021;216:1046-1047
- 6. Grewal P, Pinna P, Hall JP, Dafer RM, Tavarez T, Pellack DR, et al. Acute ischemic stroke and COVID-19: experience from a comprehensive stroke center in Midwest US. *Front Neurol* 2020;11:910
- 7. Hernández-Fernández F, Sandoval Valencia H, Barbella-Aponte RA, Collado-Jiménez R, Ayo-Martín Ó, Barrena C, et al. Cerebrovascular disease in patients with COVID-19: neuroimaging, histological and clinical description. *Brain* 2020;143:3089-3103
- 8. Kandemirli SG, Dogan L, Sarikaya ZT, Kara S, Akinci C, Kaya D, et al. Brain MRI findings in patients in the intensive care unit with COVID-19 infection. *Radiology* 2020;297:E232-E235
- 9. Klironomos S, Tzortzakakis A, Kits A, Öhberg C, Kollia E, Ahoromazdae A, et al. Nervous system involvement in coronavirus disease 2019: results from a retrospective consecutive neuroimaging cohort. *Radiology* 2020;297:E324-E334
- 10. Kremer S, Lersy F, Anheim M, Merdji H, Schenck M, Oesterlé H, et al. Neurologic and neuroimaging findings in patients with COVID-19: a retrospective multicenter study. *Neurology* 2020;95:e1868-e1882
- 11. Lin E, Lantos JE, Strauss SB, Phillips CD, Campion TR Jr, Navi BB, et al. Brain imaging of patients with COVID-19: findings at an academic institution during the height of the outbreak in New York City. AJNR Am J Neuroradiol 2020;41:2001-2008
- 12. Nawabi J, Morotti A, Wildgruber M, Boulouis G, Kraehling H, Schlunk F, et al. Clinical and imaging characteristics in patients with SARS-CoV-2 infection and acute intracranial hemorrhage. *J Clin Med* 2020;9:2543
- 13. Paterson RW, Brown RL, Benjamin L, Nortley R, Wiethoff S, Bharucha T, et al. The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. *Brain* 2020;143:3104-3120
- 14. Radmanesh A, Derman A, Lui YW, Raz E, Loh JP, Hagiwara M, et al. COVID-19-associated diffuse leukoencephalopathy and microhemorrhages. *Radiology* 2020;297:E223-E227
- 15. Radmanesh A, Raz E, Zan E, Derman A, Kaminetzky M. Brain imaging use and findings in COVID-19: a single academic center experience in the epicenter of disease in the United States. *AJNR Am J Neuroradiol* 2020;41:1179-1183
- 16. Scullen T, Keen J, Mathkour M, Dumont AS, Kahn L. Coronavirus 2019 (COVID-19)-associated encephalopathies and cerebrovascular disease: the new Orleans experience. *World Neurosurg* 2020;141:e437-e446
- 17. Yoon BC, Buch K, Lang M, Applewhite BP, Li MD, Mehan WA Jr, et al. Clinical and neuroimaging correlation in patients with COVID-19. AJNR Am J Neuroradiol 2020;41:1791-1796